

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10566068
	Filing Date		2006-01-26
	First Named Inventor	Birch	
	Art Unit		
	Examiner Name	Not yet assigned	
	Attorney Docket Number	101160-1P US	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/SY/	1	3706810		1972-12-19	American Cyanamid Company	
/SY/	2	4599198		1986-07-08	Pfizer Inc.	
/SY/	3	4668769		1987-05-26	Dennis J. Hoover	
/SY/	4	4692522		1987-09-08	Merck & Co., Inc.	
/SY/	5	4720503		1988-01-19	Merck & Co., Inc.	
/SY/	6	4751231		1988-06-14	Merck & Co., Inc.	
/SY/	7	4786641		1988-11-22	Bayer Aktiengesellschaft	
/SY/	8	4794120		1988-12-27	Synthelabo	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

/SY/	9	5863903		1999-01-26	Novo Nordisk A/S	
/SY/	10	5998463		1999-12-07	Pfizer Inc.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/SY/	1	200740	DD	A	1983-06-08	Karl Gewald et. al.		<input checked="" type="checkbox"/>
/SY/	2	4445968	DE	A1	1996-06-27	Bayer AG		<input checked="" type="checkbox"/>
/SY/	3	0697403	EP	A1	1996-02-21	Sanofi		<input checked="" type="checkbox"/>
/SY/	4	0846464	EP	A2	1998-06-10	Pfizer Inc		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

/SY/	5	0884050	EP	A1	1998-12-16	Novo Nordisk A/S		<input type="checkbox"/>
/SY/	6	0978279	EP	A1	2000-02-09	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	7	1088824	EP	A2	2001-04-04	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	8	1125580	EP	A2	2001-08-22	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	9	1134213	EP	A2	2001-09-19	Pfizer Inc.		<input type="checkbox"/>
/SY/	10	1136071	EP	A2	2001-09-26	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	11	1145717	EP	A2	2001-10-17	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	12	1149580	EP	A1	2001-10-31	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	13	1177791	EP	A2	2002-02-06	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	14	1340500	EP	A1	2003-09-03	Pfizer Products Inc		<input type="checkbox"/>
/SY/	15	2081747	ES	A1	1996-03-01	Laboratories del Dr. Esteve, S.A.		<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

	16	04179949	JP	A	1992-08-20	Fuji Photo Film CO., Ltd.	<input checked="" type="checkbox"/>
/SY/	17	2001 089368	JP	A	2001-04-03	Tanabe Seiyaku Co., Ltd	<input checked="" type="checkbox"/>
/SY/	18	2001 206856	JP	A	2001-07-31	Pfizer Products Inc.	<input checked="" type="checkbox"/>
/SY/	19	2001 247565	JP	A	2001-09-11	Pfizer Products Inc	<input checked="" type="checkbox"/>
	20	2004 196702	JP	A	2004-07-15	Yamanouchi Pharmaceuticals Co., Ltd.	<input checked="" type="checkbox"/>
/SY/	21	93/25574	WO	A1	1993-12-23	Pfizer Inc.	<input type="checkbox"/>
/SY/	22	95/24391	WO	A1	1995-09-14	Novo Nordisk A/S	<input type="checkbox"/>
/SY/	23	96/39384	WO	A1	1996-12-12	Pfizer Inc.	<input type="checkbox"/>
/SY/	24	96/39385	WO	A1	1996-12-12	Pfizer Inc.	<input type="checkbox"/>
/SY/	25	97/09040	WO	A1	1997-03-13	Novo Nordisk	<input type="checkbox"/>
/SY/	26	97/31901	WO	A1	1997-09-04	Mikael Bols	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number		101160-1P US

/SY/	27	97/45425	WO	A1	1997-12-04	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
/SY/	28	98/27108	WO	A2	1998-06-25	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
/SY/	29	98/40353	WO	A1	1998-09-17	Novo Nordisk A/S		<input type="checkbox"/>
/SY/	30	98/50359	WO	A1	1998-11-12	Novo Nordisk A/S		<input type="checkbox"/>
/SY/	31	99/26659	WO	A1	1999-06-03	Pfizer Products Inc.		<input type="checkbox"/>
/SY/	32	99/36393	WO	A1	1999-07-22	Tanabe Seiyaku Co., Ltd.		<input type="checkbox"/>
/SY/	33	00/42213	WO	A1	2000-07-20	The Research Foundation of State University of NY		<input type="checkbox"/>
/SY/	34	00/47206	WO	A1	2000-08-17	Novo Nordisk A/S		<input type="checkbox"/>
/SY/	35	01/05954	WO	A1	2001-01-25	Isis Pharmaceuticals Inc		<input type="checkbox"/>
/SY/	36	01/23347	WO	A1	2001-04-05	Novo Nordisk A/S		<input type="checkbox"/>
/SY/	37	01/32622	WO	A1	2001-05-10	AstraZeneca AB		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

	38	01/32854	WO	A2	2001-05-10	Societe de Conseils de Recherches et D'App Sci	<input checked="" type="checkbox"/>
/SY/	39	01/52825	WO	A2	2001-07-26	Novartis AG	<input type="checkbox"/>
/SY/	40	01/68055	WO	A1	2001-09-20	Pfizer Products Inc.	<input type="checkbox"/>
/SY/	41	01/68092	WO	A2	2001-09-20	Pfizer Products Inc.	<input type="checkbox"/>
/SY/	42	01/68603	WO	A2	2001-09-20	Bristol-Myers Squibb Co.	<input type="checkbox"/>
/SY/	43	01/94300	WO	A1	2001-12-13	Aventis Pharma Deutschland GMBH	<input checked="" type="checkbox"/>
/SY/	44	01/96311	WO	A2	2001-12-20	Bristol-Myers Squibb Company	<input type="checkbox"/>
/SY/	45	01/96347	WO	A1	2001-12-20	Bristol-Myers Squibb Company	<input type="checkbox"/>
/SY/	46	02/20530	WO	A1	2002-03-14	AstraZeneca AB	<input type="checkbox"/>
/SY/	47	02/26714	WO	A1	2002-04-04	Takeda Chemical Industries	<input checked="" type="checkbox"/>
/SY/	48	02/34718	WO	A1	2002-05-02	Richter Gedeon Vegyeszeti Gyar RT	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

/SY/	49	02/36583	WO	A1	2002-05-10	Shionogi & Co., Ltd.	<input checked="" type="checkbox"/>
/SY/	50	02/80844	WO	A2	2002-10-17	Genzyme Corporation	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/SY/	1	CROCHET R.A., et al., J. Het. Chem., "Synthesis of Substituted Thieno[2,3-b] pyrroles," April 1974, 143-150, Vol. 11.	<input type="checkbox"/>
/SY/	2	HARTMAN G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 1989, 1943-1949, Vol. 29(10).	<input type="checkbox"/>
/SY/	3	MCCORMACK J.G., et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy," Curr. Pharmaceutical Design, 2001, 1451-1474, Vol. 7.	<input type="checkbox"/>
/SY/	4	JAKOBSEN P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase.," Bioorganic Med. Chem., 2001, 733-744, Vol. 9.	<input type="checkbox"/>
/SY/	5	TREADWAY J.L., et al., "Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus," Exp. Opin. Invest. Drugs, 2001, 439-454, Vol. 10(3).	<input type="checkbox"/>
/SY/	6	RATH V.L. et al., "Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core," Mol. Cell, July 2000, 139-148, Vol. 6.	<input type="checkbox"/>
/SY/	7	OIKONOMAKOS N.G., et al., "Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate," Protein Sci., 1999, 1930-1945, Vol. 8.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

/SY/	8	VENKATARANGAN P., et al., "Prediction of Ligand-Receptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase," J. Med. Chem., 1999, 2169-2179, Vol. 42.	<input type="checkbox"/>
/SY/	9	HOOVER D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 1998, 2934-2938, Vol. 41.	<input type="checkbox"/>
/SY/	10	MARTIN W.H., et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," PNAS, Feb. 1998, 1776-1781, Vol. 95.	<input type="checkbox"/>
/SY/	11	SOMAN G., et al., "The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase b," Biochem. J., 1975, 369-371, Vol. 147.	<input type="checkbox"/>
/SY/	12	SOMAN G., et al. "Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase b," Biochimica et Biophysica Acta, 1974, 359-362, Vol. 358.	<input type="checkbox"/>
/SY/	13	ROSAUER K.G., et al., "Novel 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a," Bioorganic & Medicinal Chemistry Letters, 2003, 4385-4388, Vol. 13.	<input type="checkbox"/>
/SY/	14	TEAGUE J. et al., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 53, Supp. 2, 2004, A365, 1521-P.	<input type="checkbox"/>
/SY/	15	VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetologia, 2004, A214, 589, Vol. 47, Supp.1.	<input type="checkbox"/>
/SY/	16	FONT M. et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase", European Journal Med Chem, 1995, 963-71, Vol. 30.	<input type="checkbox"/>
/SY/	17	LIN T. et al. "Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats", J Pharmacology & Eptl Therapeutics, 1990, 45-50, Vol. 253(1).	<input type="checkbox"/>
/SY/	18	VARNAVAS A. et al. "Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors", Il Farmaco, 1996, 341-350, Vol. 51(5).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

/SY/	19	PARSONS W H. et al. "Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substituted Benzolactams", J Med Chem, 1989, 1681-5, Vol. 32.	<input type="checkbox"/>
/SY/	20	FREEMAN S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 2003, A340, 1470-P.	<input type="checkbox"/>
/SY/	21	TURNBULL A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 2003, A343, 1485-P.	<input type="checkbox"/>
/SY/	22	BIRCH A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, Cambridge Med Chem Symposium, Sept 2003.	<input type="checkbox"/>
/SY/	23	HUDSON S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 2002, 52-53, Vol. 539.	<input type="checkbox"/>
/SY/	24	VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich, 2004.	<input type="checkbox"/>
/SY/	25	BARTLETT J. et al., "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego, 2005.	<input type="checkbox"/>
/SY/	26	BENNETT S N L. et al., "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, Sept 2005. Poster EOM.	<input type="checkbox"/>
/SY/	27	GREEN A R. et al., "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 2004, 46474-46482, Vol. 279(45).	<input type="checkbox"/>
/SY/	28	ROBERTS P A. et al., "The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology, 2002, 297-304, Vol. 545(1).	<input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button <input type="button" value="Add"/>			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10566068
	Filing Date	2006-01-26
	First Named Inventor	Birch
	Art Unit	
	Examiner Name	Not yet assigned
	Attorney Docket Number	101160-1P US

EXAMINER SIGNATURE			
Examiner Signature	/Shawquia Young/	Date Considered	05/24/2007
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			
<p>¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.</p>			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10566068	
	Filing Date		2006-01-26	
	First Named Inventor	Birch		
	Art Unit			
	Examiner Name	Not yet assigned		
	Attorney Docket Number		101160-1P US	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
SY	1	20040002495	A1	2004-01-01	Philip Sher et. al.		
SY	2	20040082641	A1	2004-04-29	Klaus Asger Rytved et. al.		
SY	3	20040142938	A1	2004-07-22	Philip M. Sher et. al.		
SY	4	20040220229	A1	2004-11-04	Donald L. Bussolotti et. al.		

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS									Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

SY	1	02/96864	WO	A1	2002-12-05	Aventis Pharma Deutschland GmbH	<input checked="" type="checkbox"/>
SY	2	02/98348	WO	A2	2002-12-12	Eli Lilly and Company	<input type="checkbox"/>
	3	03/037884	WO	A1	2003-05-08	Japan Tobacco Inc.	<input checked="" type="checkbox"/>
SY	4	03/045920	WO	A1	2003-06-05	Merck & Co., Inc.	<input type="checkbox"/>
SY	5	03/072570	WO	A1	2003-09-04	Pfizer Products Inc	<input type="checkbox"/>
SY	6	03/074484	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	7	03/074485	WO	A2	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	8	03/074513	WO	A2	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	9	03/074517	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	10	03/074531	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	11	03/074532	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

	12	03/091213	WO	A1	2003-11-06	Yamanouchi Pharmaceutical Co., Ltd.	<input checked="" type="checkbox"/>
3Y	13	2004/031193	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
SY	14	2004/031194	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
SY	15	2004/041780	WO	A2	2004-05-21	Pfizer Products Inc.	<input type="checkbox"/>
	16	2004/078743	WO	A1	2004-09-16	Aventis Pharma Deutschland GMBH	<input checked="" type="checkbox"/>
SY	17	2004/092158	WO	A1	2004-10-28	Pfizer Products Inc	<input type="checkbox"/>
SY	18	2004/104001	WO	A2	2004-12-02	OSI Pharmaceuticals, Inc.	<input type="checkbox"/>
	19	2004/113345	WO	A1	2004-12-29	Japan Tobacco Inc.	<input checked="" type="checkbox"/>
SY	20	2005/013981	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
SY	21	2005/018637	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>
SY	22	2005/019172	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10566068
Filing Date		2006-01-26
First Named Inventor	Birch	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101160-1P US	

SY	23	2005/020985	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
SY	24	2005/020986	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
SY	25	2005/020987	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
SY	26	2005/067932	WO	A1	2005-07-28	Janssen Pharmaceutica, N.V.		<input type="checkbox"/>
SY	27	2005/085194	WO	A2	2005-09-15	Prosidion Limited		<input type="checkbox"/>
SY	28	2005/085245	WO	A1	2005-09-15	Prosidion Limited		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	<i>Shawn Young</i>	Date Considered	5/24/07
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.